JACC. Case reports · 2025
First Human Implant With Cardiac Contractility Modulation in a Patient With an Extravascular Implantable Cardioverter-Defibrillator.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kindler Jason, Silva Jose, Sackett Matthew, Mareddy Chinmaya
Аннотация
BACKGROUND: Cardiac contractility modulation (CCM) improves myocardial contractility and heart failure (HF) symptoms, whereas the extravascular implantable cardioverter-defibrillator (EV-ICD) offers defibrillation without transvenous leads. Their combined use has not been previously reported.
FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: This case presents the first documented implantation of CCM therapy in a patient with a prior EV-ICD. Lead placement and programming were optimized to prevent interference. Both devices functioned independently, with stable sensing and no inappropriate therapies. The patient experienced improved HF symptoms.
DISCUSSION: This case demonstrates the feasibility and safety of integrating CCM and EV-ICD therapy, highlighting the importance of strategic lead positioning and programming.
NOVELTY: This is the first report of CCM and EV-ICD integration, demonstrating their complementary role in HF management.
TAKE-HOME MESSAGE: CCM and EV-ICD can be safely combined, expanding options for HF patients requiring both therapies.
FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: This case presents the first documented implantation of CCM therapy in a patient with a prior EV-ICD. Lead placement and programming were optimized to prevent interference. Both devices functioned independently, with stable sensing and no inappropriate therapies. The patient experienced improved HF symptoms.
DISCUSSION: This case demonstrates the feasibility and safety of integrating CCM and EV-ICD therapy, highlighting the importance of strategic lead positioning and programming.
NOVELTY: This is the first report of CCM and EV-ICD integration, demonstrating their complementary role in HF management.
TAKE-HOME MESSAGE: CCM and EV-ICD can be safely combined, expanding options for HF patients requiring both therapies.